Business context and reporting period
Microbot Medical Inc. filed this Form 10-K for the fiscal year ended December 31, 2016. Although the request identifies 2016 Q4, the filing reports annual results, not stand-alone fourth-quarter results. Following its November 28, 2016 merger with Microbot Medical Ltd. (Microbot Israel), the company became a pre-clinical medical-device developer focused on minimally invasive micro-robotic technologies. The merger was accounted for as a reverse recapitalization, so the financial statements principally reflect Microbot Israel’s historical business. The former StemCells stem-cell assets were substantially sold on November 29, 2016.
The company’s two lead candidates are the Self-Cleaning Shunt (SCS) for hydrocephalus and normal-pressure hydrocephalus, and TipCAT, a self-propelling endoscope initially intended for colonoscopy. Neither product was approved for sale, and Microbot reported no product revenue.
Financial results and position
| Metric | 2016 | 2015 |
|---|---|---|
| Revenue from product sales | None | None |
| Research and development expense, net | $901,000 | $823,000 |
| General and administrative expense | $8.734 million | $92,000 |
| Operating loss | $9.635 million | $915,000 |
| Net loss | $9.663 million | $921,000 |
| Net cash used in operating activities | $786,000 | $765,000 |
| Net cash provided by financing activities | $3.083 million | $413,000 |
| Cash and cash equivalents at year-end | $2.709 million | $437,000 |
The loss per share was $0.40 in 2016 versus $0.04 in 2015. Margins are not meaningful because the company had no product revenue. The sharp increase in G&A was primarily merger-related: approximately $7.258 million for shares issued for services in the transaction and $676,000 of share-based compensation, alongside higher legal and professional costs. The filing’s cash-flow statement shows a $2.272 million increase in cash during 2016.
Year-end current assets were $3.315 million and current liabilities were $783,000, implying working capital of approximately $2.532 million. The MD&A separately states working capital of approximately $2.495 million; the filing does not reconcile this difference. Long-term liabilities included a $2.029 million convertible note to Alpha Capital, due November 28, 2019, bearing 6% annual interest and convertible at $0.64 per share beginning November 28, 2017; its year-end balance-sheet carrying value was $76,000. Contractual obligations also included $90,000 of capital-lease payments. No off-balance-sheet arrangements were reported.
Changes versus the prior comparable period
- Net loss rose to $9.663 million from $921,000, chiefly because of merger-related and share-based costs rather than a comparable increase in product-development activity.
- R&D expense increased modestly, by $78,000 in the results table, while operating cash use was broadly similar to 2015.
- Year-end cash increased to $2.709 million from $437,000, supported by financing, the merger-related asset transaction, and other transaction cash flows.
- The merger, company-name change, reverse stock split, and sale of the former stem-cell assets substantially changed the business and capital structure. Accordingly, comparisons with 2015 should be read in light of the reverse recapitalization and the different business scope.
Outlook, risks, contingencies and unusual items
Management expected continued losses and increasing development costs, with no significant revenue anticipated until products are developed, cleared or approved, and commercialized. It stated that available net cash was expected to fund operations for at least 12 months. Subsequent to year-end, the company sold 700,000 shares for $3.5 million gross proceeds (approximately $3.25 million net); the financial-statement note reported cash and cash equivalents of approximately $6.7 million as of issuance.
Management aimed to complete pre-clinical studies needed for regulatory submissions for both candidates within 24 months. For SCS, a January 2017 Washington University agreement provided for an initial study expected to take six months, at an estimated cost of $130,000, followed by a comprehensive study expected in 2018. TipCAT animal studies were planned, but timing varies within the filing: the business section says late 2017, while the risk discussion says 2018. Management anticipated possible FDA 510(k) or de novo pathways, but classification and the need for human trials were not determined. These schedules and pathways are plans, not assured outcomes.
- Funding and dilution: The company had no committed external funding source and may need additional equity, debt, grants, or partners; financing may dilute shareholders or constrain operations.
- Development and regulatory risk: Both candidates remained pre-clinical. Animal or human studies, FDA review, product acceptance, reimbursement, and commercial manufacturing could delay or prevent commercialization.
- License and grant obligations: The Technion license requires development milestones and carries sales and sublicensing royalties; missing milestones could permit termination. Israeli Innovation Authority grants carry royalty obligations and restrictions on transferring supported technology outside Israel.
- Other risks: Microbot relies on third-party manufacturers, has limited operating history, faces competition and intellectual-property risks, and has exposure to Israeli operating conditions and currency movements. Certain outstanding warrants have anti-dilution terms; the company also disclosed a possible future share repurchase of up to $500,000, subject to final agreements and conditions.
- Unusual transaction accounting: The merger included 7.8 million shares or rights issued to advisers, with a reported $7.258 million charge in G&A. The company reported no material pending legal proceedings. The independent auditor issued an unqualified opinion on the financial statements; management said disclosure controls and internal control over financial reporting were effective, without auditor attestation of internal controls.
Important facts for investors to verify
- Reconcile the R&D expense inconsistency: the audited statements and MD&A table report $901,000, while MD&A narrative says approximately $948,000.
- Reconcile the working-capital figures: approximately $2.532 million from the balance-sheet amounts versus $2.495 million stated in MD&A.
- Confirm the TipCAT animal-study schedule, which is described as late 2017 in one section and 2018 in another.
- Review the terms, carrying value, conversion features, and maturity of the Alpha Capital note, as well as subsequent equity financing and potential dilution.
- Track SCS and TipCAT study results, FDA requirements and timelines, Technion milestone compliance, and the company’s actual cash runway relative to its stated plans.